This year’s jury comprises industry luminaries actively involved and committed to shaping the Indian healthcare industry.
NephroLife, Sparsh Nephrocare and Deep Chand Dialysis are other peers that have attracted PE funding.
Deal values Syngene at a premium to the recent transaction where Biocon bought back GE Capital's stake.
The firm is expected to file documents for IPO next month.
It counts Ronnie Screwvala as a shareholder.
Congrates Manas. Keep it up. This is B S Yadav from Indo gulf .
Good article. Few comments:
1. Many times "starting a new fund" sounds a good reason for an exit; exit may be...
Why did he leave CG?